Bioxytran, Inc. (OTCMKTS:BIXT) Sees Large Decrease in Short Interest

Bioxytran, Inc. (OTCMKTS:BIXT) saw a significant decrease in short interest in the month of October. As of October 15th, there was short interest totaling 300 shares, a decrease of 84.2% from the September 30th total of 1,900 shares. Based on an average daily trading volume, of 254,400 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the company’s stock are short sold. Approximately 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 254,400 shares, the short-interest ratio is presently 0.0 days.

Bioxytran Stock Performance

Bioxytran stock opened at $0.05 on Tuesday. The firm has a market capitalization of $4.19 million, a PE ratio of -1.57 and a beta of 1.35. The stock’s 50 day moving average price is $0.07 and its 200 day moving average price is $0.10. Bioxytran has a one year low of $0.04 and a one year high of $0.23.

Bioxytran Company Profile

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.